Fibroblast growth factor 1 (FGF-1) shows strong angiogenic, osteogenic and tissue-injury repair properties that might be relevant to medical applications. Since FGF-1 is partially unfolded at physiological temperature we decided to increase significantly its conformational stability and test how such an improvement will affect its biological function. Using an homology approach and rational strategy we designed two new single FGF-1 mutations: Q40P and S47I that appeared to be the most strongly stabilizing substitutions among those reported so far, increasing the denaturation temperature by 7.8 deg. C and 9.0 deg. C, respectively. As our goal was to produce highly stable variants of the growth factor, we combined these two mutations with five previously described stabilizing substitutions. The multiple mutants showed denaturation temperatures up to 27 deg. C higher than the wild-type and exhibited full additivity of the mutational effects. All those mutants were biologically competent in several cell culture assays, maintaining typical FGF-1 activities, such as binding to specific cell surface receptors and activation of downstream signaling pathways. Thus, we demonstrate that the low denaturation temperature of wild-type FGF-1 is not related to its fundamental cellular functions, and that FGF-1 action is not affected by its stability. A more detailed analysis of the biological behavior of stable FGF-1 mutants revealed that, compared with the wild-type, their mitogenic properties, as probed by the DNA synthesis assay, were significantly increased in the absence of heparin, and that their half-lives were extensively prolonged. We found that the biological action of the mutants was dictated by their susceptibility to proteases, which strongly correlated with the stability. Mutants which were much more resistant to proteolytic degradation always displayed a significant improvement in the half-life and mitogenesis. Our results show that engineered stable growth factor variants exhibit enhanced and prolonged activity, which can be advantageous in terms of the potential therapeutic applications of FGF-1.
Submitter: Shu-Ching Ou
Submission Date: Sept. 29, 2018, 10:06 a.m.
|Number of data points||252|
|Proteins||Fibroblast growth factor 1|
|Assays/Quantities/Protocols||Experimental Assay: T_den (Circular Dichroism) ; Experimental Assay: ΔH_den (Circular Dichroism) ; Experimental Assay: ΔG_den (Circular Dichroism) ; Experimental Assay: T_den (Fluorescence Spectroscopy) ; Experimental Assay: ΔH_den (Fluorescence Spectroscopy) ; Experimental Assay: ΔG_den (Fluorescence Spectroscopy) ; Experimental Assay: EC50 (+Heparin): serum-starved NIH 3T3 cells to incorporate [3H]thymidine ; Experimental Assay: Specific Mitogenic Activity (+Heparin): serum-starved NIH 3T3 cells to incorporate [3H]thymidine ; Experimental Assay: EC50 (-Heparin): serum-starved NIH 3T3 cells to incorporate [3H]thymidine ; Experimental Assay: Specific Mitogenic Activity (-Heparin): serum-starved NIH 3T3 cells to incorporate [3H]thymidine ; Derived Quantity: ΔT_den (Circular Dichroism) ; Derived Quantity: ΔT_den (Fluorescence Spectroscopy)|
|Libraries||Thermodynamic parameters ; Specific mitogenic activity and EC50 for mitogenic activity of the FGF-1 variants|